When did the Coreg patents expire?
The original patent protecting carvedilol, the active ingredient in Coreg, was issued in the late 1980s and expired in the early 2000s. Most formulation and method patents that followed also reached their expiration dates by the mid‑2010s, leaving the core compound unprotected in the United States.
[1]
Are there still any patents protecting Coreg?
No active patents cover the carvedilol molecule itself. A handful of patents on specific salt forms and extended‑release formulations exist, but all have either expired or are approaching expiration. Consequently, the drug is fully eligible for generic entry.
[1]
What does patent expiry mean for generic competition?
Once patents lapse, generic manufacturers can file Abbreviated New Drug Applications (ANDAs) to market carvedilol. Because the active ingredient is no longer protected, price competition has intensified. Generics typically launch 3‑5 years after patent expiration, but several generic versions have already entered the market.
[2]
Which generics are on the market and when did they launch?
Generic carvedilol became available in 2013, following the expiration of the last major patent. Multiple manufacturers, including Teva, Mylan, and Sandoz, now sell carvedilol capsules and tablets. These generics are interchangeable with Coreg once they meet FDA bioequivalence standards.
[2]
Are there any new patents for formulations or uses?
Recent filings focus on novel sustained‑release formulations and fixed‑dose combinations with other antihypertensives. While these patents may grant temporary market exclusivity, they do not shield the basic carvedilol compound from generic competition.
[1]
What impact does this have on pricing?
Generic entry has lowered the average cost of carvedilol by up to 70 %. Insurers and pharmacy benefit managers now typically prefer generic carvedilol, and the drug’s formulary placement has shifted accordingly. The price advantage is most pronounced in large therapeutic areas such as heart failure and hypertension.
[2]
Who owns the remaining patents?
Pfizer, the current owner of Coreg, holds a small portfolio of patents related to advanced delivery systems. Other companies hold patents on specific salt forms or combination therapies, but none provide market exclusivity for the core drug.
[1]
Are there any legal disputes about carvedilol patents?
A handful of litigation cases in the 2010s addressed alleged infringement of formulation patents. All were settled out of court, and no ongoing disputes threaten generic availability.
[1]
What should patients and prescribers consider?
Because carvedilol is generic‑eligible, prescribers can choose between Coreg and lower‑priced generic formulations. Patients should verify that their prescriber confirms the drug’s equivalence, especially when switching from Coreg to a generic. Insurance coverage, copay tiers, and prior‑authorization policies may influence the choice.
Sources
[1] https://drugpatentwatch.com
[2] FDA Generic Drugs Database